us investment journal Hi all,
This is off ozestock!
Eiffel gets mention in premier US investment journal: The Motley Fool.
"Skyepharma (Nasdaq: SKYE) estimates that 40% of drug candidates are abandoned at an early stage due to the body's inability to absorb the drug. The company's nanoparticulate drug-delivery technology promises to remove a lot of these barriers, open up new opportunities, and widen the market for some current drugs on the market.
Other companies working on nanoparticulate drug delivery are Elan Drug Delivery, part of Elan Corp. (NYSE: ELN), Eiffel Technologies in Australia, and Eli Lilly (NYSE: LLY) courtesy of Applied Molecular Evolution, now a wholly owned subsidiary of Eli Lilly after their recent merger. There are a host of private companies also working in this field."
Regards,
xmagx
EIF
eiffel technologies limited
